KCT0004571
进行中（未招募）
未知
Phase II trial evaluating the efficacy and safety of physician chosen chemotherapy with hormonal therapy in patients with heavily pretreated advanced ovarian cancer: A multicenter pilot study
适应症Neoplasms
概览
- 阶段
- 未知
- 干预措施
- 未指定
- 疾病 / 适应症
- Neoplasms
- 发起方
- Inha University Hospital
- 入组人数
- 58
- 状态
- 进行中（未招募）
- 最后更新
- 去年
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •\- Patients with epithelial ovarian, primary peritoneal, or fallopian tube cancer (EOC): including all histologic types
- •\-Confirmation of recurrence using biopsy from primary or metastatic tissue
- •\-Palliative treatment setting: \[(previous progression free or treatment free interval \< 6months and 2 prior chemotherapy regimens) or (\=3 prior chemotherapy regimens)]
- •\-ECOG Performance status 0\-2
- •\-Measurable lesion
- •\- Estimated life time \=6months
- •\- Adequate hematologic and end organ function
- •\- During clinical trial, women of reproductive age should undergo adequate contraception, and should not perform breast feeding. Moreover, women should have negative pregnancy test performed immediately before clinical trial
排除标准
- •\-Patients who were diagnosed with other type of primary cancer within 5 years from diagnosis of epithelial ovarian, primary peritoneal, or fallopian tube cancer (EOC): except cervical intraepithelial neoplasm
- •\-Cases that investigator decides as inadequate for study
- •\-Patient who has not been recovered from recent surgery
- •\-Patient having toxicity more than grade 2 of CTCAE originated from previous chemotherapy
- •\-Patient receiving immunotherapy or targeted therapy as anticancer therapy
- •\-History of venous thromboembolism
- •\-Pregnant women or women having possibility of pregnancy
- •\-Hypersensitivity for tamoxifen
- •\-Patient receiving combined therapy with Anstrozole
- •\-Patient having genetic disorders such as galactose intolerance, lapp lactase deficiency or glucose\-galactose malaborption
结局指标
主要结局
未指定
相似试验
已完成
2 期
A phase II trial evaluating the safety and efficacy of the addition of concurrent anti-PD-1 nivolumab to standard first-line chemotherapy and radiotherapy in locally advanced stage IIIA/B Non-Small Cell Lung Carcinomalocally advanced non-small cell lung cancer1003866610029107NL-OMON44704European Thoracic Oncology Platform (ETOP)18
进行中（未招募）
1 期
Trial to evaluate how severe the side effects are and how well the addition of Nivolumab to standard treatment works in patients with advanced NSCLC.locally advanced stage IIIA/B NSCLCMedDRA version: 20.0Level: PTClassification code 10029520Term: Non-small cell lung cancer stage IIIASystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2014-005097-11-BEETOP (European Thoracic Oncology Platform)78
进行中（未招募）
1 期
Phase II clinical trial to evaluate safety and efficacy of mobilisation and collection of CD34+ cells after treatment with plerixafor and filgrastim in patients with Fanconi anaemia for subsequent transduction with a lentiviral vector carrying the FANCA gene and reinfusion into the patient - Fancostem-Plerixafor & Filgrastim mobilisation in Fanconi AnaemiaEUCTR2014-004272-29-GBGreat Ormond Street Hospital NHS foundation Trust20
进行中（未招募）
1 期
A Phase II trial to assess the efficacy and safety ofpasireotide s.c. alone or in combination with cabergoline inpatients with Cushing’s diseaseCushing's diseaseEUCTR2013-002170-49-GRovartis Pharma Services AG128
进行中（未招募）
1 期
A Phase II trial to assess the efficacy and safety ofpasireotide s.c. alone or in combination with cabergoline inpatients with Cushing’s diseaseCushing's diseaseEUCTR2013-002170-49-FRovartis Pharma Services AG128